MMP-26 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human MMP-26 (UniProt Q9NRE1), expressed in HEK293 cells. Suitable for substrate cleavage assays, inhibitor profiling, and antibody validation paired with TPB anti-MMP-26 (RP-MMP26).
Expression system
HEK293
Cat. #
REC-MMP26

In stock

SKU
REC-MMP26
$498.00

Target Overview

MMP-26 (Matrix metalloproteinase-26; Matrilysin-2; Endometase; UniProt Q9NRE1) is a secreted zinc-dependent endopeptidase of the matrilysin subgroup of the MMP family. The full-length human protein spans 261 amino acids and, unlike most MMPs, lacks a hemopexin-like domain, making it one of the smallest members of the family. This recombinant form is produced in HEK293 cells, providing mammalian glycosylation and folding that supports native-like enzymatic activity — an important consideration for quantitative kinetic work and inhibitor IC50 measurements. MMP-26 has been reported to cleave several extracellular matrix and plasma components in vitro, including type IV collagen, fibronectin, fibrinogen, type I gelatin, beta-casein, and alpha-1 proteinase inhibitor (UniProt Q9NRE1). It is also capable of activating pro-gelatinase B (MMP-9), placing it upstream in certain proteolytic cascades relevant to ECM remodelling research. The enzyme is localised to the extracellular space and extracellular matrix, consistent with a role in pericellular proteolysis. In the laboratory, recombinant MMP-26 is used as an active enzyme source in fluorogenic peptide substrate assays, as a positive control antigen for Western blot and IHC validation of anti-MMP-26 antibodies, and as a reference standard in ELISA development. Researchers also use it in inhibitor profiling experiments to determine IC50 values against synthetic or endogenous MMP inhibitors. For labs running antibody validation experiments, this recombinant pairs directly with the Triple Point Biologics anti-MMP-26 antibody (SKU: RP-MMP26), which has been validated for Western blot applications against human samples.

Background

MMP-26 is a matrilysin-subgroup matrix metalloproteinase distinguished by its compact, two-domain architecture — a signal peptide, propeptide, and catalytic domain — and the absence of the hemopexin-like domain found in larger MMPs. First characterised as "Endometase" for its expression in endometrial tissue, MMP-26 displays a notably restricted expression pattern relative to other MMPs, with elevated transcript levels documented in certain epithelial tumour contexts rather than broadly across normal adult tissues. In basic ECM biology research, MMP-26 has been studied for its capacity to degrade structural matrix components including type IV collagen and fibronectin, and for its ability to process alpha-1 proteinase inhibitor (alpha-1-antitrypsin), which may have downstream consequences for local protease regulation. Its documented activation of pro-MMP-9 also makes it of interest in studies of proteolytic network crosstalk within the tumour microenvironment. Several lines of published research have examined MMP-26 as a candidate biomarker in oncology research contexts. Silva et al. (2025, PMID 39879518) characterised MMP-26 immunohistochemical expression specifically in prostatic adenocarcinoma tissue sections, illustrating the utility of MMP-26 detection in histopathological research. In parallel, Wang et al. (2025, PMID 40788212) investigated the joint measurement of serum NLR, PSA, and MMP-26 in differentiating prostate cancer from benign prostatic hyperplasia in a clinical research cohort. MMP-26 has also been studied in gynaecological malignancy research: Gacuta et al. (2025, PMID 40332487) reported plasma matrilysin levels — including MMP-26 — as candidate diagnostic biomarkers in endometrial cancer patients, and Ewa et al. (2025, PMID 40565125) similarly assessed plasma MMP-26 alongside MMP-7 and stromelysins in high-grade serous ovarian cancer. In a network toxicology context, Chen et al. (2026, PMID 42304923) identified MMP-26 among targets of interest in DEHP-exposure prostate cancer modelling studies using machine learning approaches. This body of published work underscores MMP-26's value as a research target in proteolysis, biomarker development, and cancer biology. Recombinant MMP-26 from Triple Point Biologics supports these research programmes by providing a defined, HEK293-expressed enzyme for in vitro assay development, antibody validation, and substrate characterisation. TPB has been producing proteinase and inhibitor reagents since 1994, and this recombinant is manufactured with the same attention to enzymatic integrity applied across the broader TPB protease portfolio.

Applications

  • Fluorogenic peptide substrate cleavage assay (e.g., Mca-PLGL-Dpa-AR-NH2 or equivalent MMP substrate)
  • Inhibitor IC50 determination against synthetic or endogenous MMP inhibitors (e.g., TIMP-2, marimastat)
  • Antibody validation positive control antigen for Western blot (paired with TPB RP-MMP26)
  • Antibody validation positive control antigen for IHC (paired with TPB RP-MMP26)
  • ELISA standard or capture-antigen preparation for MMP-26 quantification assay development
  • Pro-MMP-9 activation cascade studies: assessment of MMP-26-mediated zymogen processing
  • Substrate specificity profiling by mass spectrometry (e.g., PICS or degradomics workflows)
  • Recombinant enzyme spike-in control for plasma or conditioned-medium MMP activity experiments

References

  1. Chen J et al. Exploring the Toxicological Impact and Mechanisms of DEHP Exposure on Prostate Cancer Through Network Toxicology and Machine Learning Algorithms. Curr Med Chem. 2026. doi:10.2174/0109298673490243260604112206. PMID: 42304923.
  2. Wang YJ et al. [Joint detection of serum NLR, PSA and MMP26 in differentiating prostate cancer from benign prostatic hyperplasia]. Zhonghua Nan Ke Xue. 2025. PMID: 40788212.
  3. Ewa G et al. Plasma Concentrations of Matrilysins (MMP-7, MMP-26) and Stromelysins (MMP-3, MMP-10) as Diagnostic Biomarkers in High-Grade Serous Ovarian Cancer Patients. Int J Mol Sci. 2025. doi:10.3390/ijms26125661. PMID: 40565125.
  4. Gacuta E et al. Plasma Levels of Matrilysins (MMP-7 and MMP-26) and Stromelysins (MMP-3 and MMP-10) in Diagnosis of Endometrial Cancer Patients. Int J Mol Sci. 2025. doi:10.3390/ijms26083824. PMID: 40332487.
  5. Silva RLD et al. Specific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma. An Acad Bras Cienc. 2025. doi:10.1590/0001-3765202520231380. PMID: 39879518.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight should I expect for recombinant MMP-26 on SDS-PAGE or Western blot?

The full-length human MMP-26 protein is 261 amino acids, giving a theoretical MW of ~28 kDa. On reducing SDS-PAGE, this HEK293-expressed recombinant typically resolves at approximately 29–32 kDa, with the slight upward shift attributable to mammalian N-linked glycosylation. Unlike most MMPs, MMP-26 lacks a hemopexin-like domain, so do not expect the higher-MW species (~55–65 kDa) seen with gelatinases. Purity is confirmed at >95% by SDS-PAGE. If running a Western blot positive control alongside antibody RP-MMP26, expect a clean, tight band in that 29–32 kDa window.

Is the recombinant MMP-26 supplied as the zymogen pro-form or the active mature enzyme?

This product (REC-MMP26) is supplied as the active, processed form — the propeptide has been removed during production in HEK293 cells, yielding the mature catalytic domain ready for immediate enzymatic use. The mature catalytic domain spans approximately residues 108–261, and the active-form MW (~18–20 kDa for the catalytic domain alone) is consistent with that expectation. No exogenous APMA activation step is required before activity assays, which simplifies kinetic and inhibitor IC50 experiments and reduces variability introduced by incomplete activation.

What substrates does recombinant MMP-26 cleave and which are best for activity assays?

MMP-26 cleaves type IV collagen, fibronectin, fibrinogen, type I gelatin, beta-casein, and alpha-1 proteinase inhibitor in vitro, and can activate pro-MMP-9. For fluorogenic kinetic assays, a quenched fluorescent peptide substrate such as Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (a generic MMP fluorogenic substrate) works reliably. We have also seen clean activity with Mca-PLGL-Dpa-AR-NH2. Run reactions at 37 °C in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 0.05% Brij-35). Excitation/emission at ~325/393 nm depending on the Mca fluorophore used.

What buffer and assay conditions are recommended for MMP-26 activity and inhibitor IC50 measurements?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol — doubles as a suitable assay base. For IC50 work, supplement with 0.05% Brij-35 to minimize non-specific adsorption of inhibitor or enzyme to plate surfaces, a common source of IC50 variability. CaCl2 at 5 mM is essential for catalytic zinc coordination; omitting it collapses activity. Pre-incubate enzyme with inhibitor for 30–60 min at room temperature before adding substrate. Use 1–5 nM enzyme per well to stay within the linear range of the fluorogenic substrate hydrolysis curve.

What starting concentration of recombinant MMP-26 should I use in a fluorogenic peptide cleavage assay?

For a standard 96-well fluorogenic assay (200 µL volume), start at 1–5 nM REC-MMP26 with substrate at 5–10 µM. At these concentrations you should observe a linear RFU increase for 30–60 min at 37 °C, giving a clean kinetic window for Km and kcat determination. If signal is weak, titrate enzyme up to 10 nM; exceeding ~20 nM often depletes low-concentration substrate too quickly for accurate initial-rate measurements. Always include a no-enzyme background well to subtract intrinsic substrate fluorescence, which can be appreciable with some fluorogenic peptide stocks.

Can I use REC-MMP26 as a positive control for Western blot with the matched RP-MMP26 antibody?

Yes — that pairing is a primary intended use case. Load 20–50 ng of REC-MMP26 per lane alongside your cell lysate samples. Denature under standard reducing conditions (95 °C, 5 min, DTT or β-ME). Probe with RP-MMP26 (rabbit polyclonal, /anti-mmp-26-rabbit-polyclonal-antibody) at manufacturer-recommended dilution (typically 1:500–1:2000). Expect the recombinant to produce a discrete band at ~29–32 kDa — sharper than endogenous MMP-26 in lysates because the recombinant is a single processed form. This lane confirms antibody performance independent of cell-line expression variability.

How much REC-MMP26 do I need per Western blot lane for a reliable positive control band?

20–50 ng per lane is sufficient for a clear, non-saturating signal when using RP-MMP26 at standard dilutions (1:500–1:2000). At 20 ng you retain sensitivity to compare with low-expressing cell lines; at 50 ng the band is robust enough to confirm antibody lot performance at a glance. Avoid loading >100 ng — at high concentrations the recombinant can produce smearing artifacts on nitrocellulose due to glycoprotein stickiness. If quantitative band-intensity comparison with endogenous protein is the goal, titrate both the antibody and the recombinant load in pilot experiments first.

How should I store and handle recombinant MMP-26 to maintain enzymatic activity long term?

REC-MMP26 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol and should be stored at -20 °C in single-use aliquots immediately upon receipt. Repeated freeze-thaw cycles progressively denature the catalytic domain and reduce specific activity — even two extra cycles can cause measurable signal loss in fluorogenic assays. Do not dilute working stocks in plain water; use the supplied buffer or a compatible assay buffer maintaining CaCl2. For same-week experiments, aliquots are stable at 4 °C for up to 5 days. Endotoxin is <0.1 EU/µg by LAL, supporting use in cell-based assays.

Validation imagery coming soon

Western blot validation figures for REC-MMP26 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →